Jun 01 2021
Opposition to a second Japanese patent, applied for in relation to the use of CRISPR methods in cellular studies, has been rejected by the Japanese Patent Office (JPO), reports ERS Genomics, the Dublin-based company providing access to this technology.
“The JPO actions reinforce the broad and fundamental nature of our CRISPR patent portfolio, both in Japan and worldwide.” Michael Arciero
Japanese patent (JP6692856), filed by CRISPR/Cas9 intellectual property co-owner Dr. Emannuelle Charpentier, together with The Regents of the University of California and University of Vienna (collectively known as CVC), covers compositions and methods for use in a variety of eukaryotic cells, in either dual-guide or single-guide format.
On May 20, 2021, the ITC issued a Notice of Investigation in
Certain Wearable
Electronic Devices With ECG Functionality and Components
Thereof (Inv. No. 337-TA-1266).
By way of background, this investigation is based on an April
20, 2021 complaint (
seePart I, Part II, Part III, Part IV) filed by AliveCor, Inc. of
Mountain View, California ( AliveCor ) alleging a
violation of section 337 by Apple, Inc. of Cupertino, California
( Apple ) in the unlawful importation and/or sale in the
U.S. of certain wearable electronic devices with electrocardiogram
(ECG) functionality and components thereof by reason of
infringement of one or more claims of U.S. Patent No. 10,595,731
If you re perplexed by the Biden Administration’s waiver of COVID19 vaccine patent protection in the name of accelerating the inoculation of mass population segments of poor countries being ravaged by the disease, you are not alone. Even we veteran trade negotiators are scratching our heads.